Objective: The purpose is to study the clinical curative effect of Liuwei Wuling tablet in the treatment of liver fibrosis in hepatitis B and its influences on the determination of monoamine oxidase (MAO) and transforming growth factor β1(TGF-β1). Method: Eighty-four cases of patients were randomly divided into observation group (42 cases) and control group (42 cases). Patients in both groups all took the conventional treatment (eg

vitamins

liver-protect drugs) and the entecavir by oral

0.5 mg/time

1 time/day. The patients in observation group took Liuwei Wuling tablet

1.5 g/time

3 times/day. The treatment course of two groups was 24 weeks. The liver function

liver fibrosis indexes

MAO and TGF-β1 were tested before and after the treatment

examining liver and spleen by ultrasound B. Result: After the treatment

the total effective rate of observation group was 90.5%

Better than the control group 61.9% in the control group(P<0.01). The level of Alanine aminotransferase(ALT)

aspartate transaminase(AST) and total bilirubin(TBIL) of observation group was lower than those of control group (P<0.01). Also

the serum hyaluronic acid(HA)

laminin(LN)

procollagen type Ⅲ(PCⅢ) and collagen type Ⅳ(Ⅳ-C) level of observation group were lower than the control group (P<0.01). The serum MAO and TGF-β1 level of the two groups were obviously decreased and the decline in observed group was more significantly (P<0.01). The spleen thickness of patients in observation group was lower than the control group after treatment (P<0.05). Conclusion: Liuwei Wuling tablet can inhibit the expression of serum MAO and TGF-β1 of the hepatitis B liver fibrosis patients

further to inhibit the activation of hepatic stellate cells

preventing the development of liver fibrosis. The clinical curative effect of Liuwei Wuling tablet is significant and worthy of promotion.